Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supercharged immune cells take on Hard-to-Treat pancreatic cancer

NCT ID NCT07145450

Recruiting now Disease control Sponsor: Anocca AB Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new therapy that takes a patient's own immune T-cells, engineers them to recognize and attack pancreatic cancer cells with specific KRAS mutations, and infuses them back. The study includes 96 adults with advanced pancreatic cancer who have the right genetic markers. The goal is to see if the treatment is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TCR-T cells (engineered immune cells targeting mutated KRAS proteins)
What this could lead to
If successful, this could lead to a new treatment option for advanced pancreatic cancer by training the immune system to attack cancer cells with specific mutations.
What could go wrong
This is an early first-in-human trial, so safety and effectiveness are not yet known. The therapy requires chemotherapy beforehand and may cause serious side effects. Only patients with specific genetic profiles can participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PDAC

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Amsterdam UMC - VU Medical Center

    RECRUITING

    Amsterdam, Netherlands

  • Charité Universitätsmedizin Berlin

    RECRUITING

    Berlin, Germany

  • Herlev and Gentofte University Hospital

    RECRUITING

    Copenhagen, Denmark

  • Karolinska University Hospital

    RECRUITING

    Stockholm, Sweden

  • Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum der Universitaet Muenchen - Campus Grosshadern - Medizinische Klinik und Poliklinik III

    NOT_YET_RECRUITING

    München, Germany

  • Radboud University Medical Center

    RECRUITING

    Nijmegen, Netherlands

  • Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus

    RECRUITING

    Dresden, Germany

  • Universitaetsklinikum Heidelberg

    RECRUITING

    Heidelberg, Germany

  • Universitaetsklinikum Leipzig - Universitaeren Krebszentrum (UCCL)

    NOT_YET_RECRUITING

    Leipzig, Germany

  • University Hospital and Faculty of Medicine Eberhard Karls University Tübingen

    RECRUITING

    Tübingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.